Macedonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
mesothelioma/пролив
Врската е зачувана во таблата со исечоци
Страница 1 од 49 резултати
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Twenty-five patients with histologically proven malignant mesothelioma participated in a trial of imatinib mesylate (Glivec) with a starting dose of 400 mg per day taken orally, up to a maximal dose of 800 mg. No responses were observed in the patient group, while three patients showed prolonged (>6
Malignant peritoneal mesothelioma presenting with persistent high fever.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Malignant peritoneal mesothelioma (MPM) is a rare tumor that develops in the peritoneum. In this paper, we describe an extremely rare case of MPM metastasizing to the appendix in a 48-year-old female who initially presented with a persistent high fever. The woman reported a slight lower abdominal
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
We conducted a phase 2, multicenter, open-label study of erlotinib plus bevacizumab in patients with malignant pleural mesothelioma who had previously received 1 prior chemotherapy regimen. These agents have activity in non-small cell lung cancer, but their role in mesothelioma is
A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
We conducted a phase II multicenter trial to evaluate the activity of combined gemcitabine and oxaliplatin in malignant pleural mesothelioma. Twenty-five patients were recruited between May 1999 and December 2001 and received gemcitabine 1000 mg/m2 intravenously over 30 minutes and oxaliplatin 80
[Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 - A Case Report].
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Malignant mesothelioma is a rare aggressive solid tumor that is invariably incurable. A 23-year-old female patient with ascites, anemia, and high levels of ferritin and CRP was diagnosed with pleural mesothelioma by exploratory laparotomy. She remained asymptomatic, but 7 years later, she developed
Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Peritoneal mesothelioma is a rare malignancy that is seen in patients exposed to asbestos or in young women with no known exposure to asbestos. The clinical features of the disease are similar in these two groups, and include peritoneal carcinomatosis, ascites, thrombocytemia, systemic symptoms
An Unpleasant Surprise: Abdominal Presentation of Malignant Mesothelioma
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Malignant mesothelioma is an aggressive cancer associated with asbestos exposure with median survival time of 8 to 14 months following diagnosis. Given that mesothelial cells also line the peritoneum and pericardium, malignant mesothelioma can present in unusual sites and in patients with
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite,
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
We chose to treat malignant pleural mesothelioma with a combination of docetaxel and irinotecan (CPT-11), because there have been preliminary reports that CPT-11 is active against mesothelioma, and docetaxel and CPT-11 were the most active agents in our in vitro experiments in human mesothelioma
Malignant peritoneal mesothelioma diagnosed 50 years post-radiotherapy for ovarian cancer in a patient with a history of multiple malignancies: An autopsy case.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
As the number of long-term cancer survivors is increasing, the incidence of post-irradiation malignant mesothelioma may also increase. We herein present the case of an 85-year-old female patient with a history of several surgeries for solid tumors and radiotherapy to the pelvis, who presented with
Impact of New Chemotherapeutic agents on the outcome of Egyptian patients with Advanced Malignant Pleural Mesothelioma.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Patients with malignant pleural mesothelioma (MPM) are well known to have poor response to chemotherapy. Aim of this work was to evaluate the efficacy and safety of new chemotherapeutic agents for the treatment of Egyptian MPM patients.
METHODS
The first study was a non-randomized, open-label trial.
[Diagnosis and treatment of 41 patients with malignant peritoneal mesothelioma].
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
OBJECTIVE
To study the methods of diagnosis and treatment of malignant peritoneal mesothelioma.
METHODS
The clinical data of 41 patients with malignant peritoneal mesothelioma pathologically confirmed were retrospectively analyzed.
RESULTS
Of these 41 patients, abdominal pain and diarrhea were found
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
OBJECTIVE
The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity of irinotecan in malignant mesothelioma (CALGB protocol 9733).
METHODS
Twenty-eight patients accrued between January 1998 and January 1999 received irinotecan 125 mg/m2 by intravenous
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
OBJECTIVE
The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807).
METHODS
Between November 15, 2000 and August 31, 2001, 27 patients with mesothelioma were enrolled in this study. Capecitabine was
Најкомплетната база на податоци за лековити билки поддржана од науката
- Работи на 55 јазици
- Лекови од билки поддржани од науката
- Препознавање на билки по слика
- Интерактивна GPS мапа - означете ги билките на локацијата (наскоро)
- Прочитајте научни публикации поврзани со вашето пребарување
- Пребарувајте лековити билки според нивните ефекти
- Организирајте ги вашите интереси и останете во тек со истражувањето на новостите, клиничките испитувања и патентите
Напишете симптом или болест и прочитајте за билки што можат да помогнат, напишете билка и видете болести и симптоми против кои се користи.
* Сите информации се базираат на објавени научни истражувања
